	ROCKVILLE, Md. and CAMBRIDGE, England, Feb. 5, 2015 /PRNewswire-USNewswire/ -- Accelovance, Inc. (Accelovance), a Contract Research Organization (CRO) therapeutically aligned in the areas of Oncology, Vaccines, and General Medicine; today announced it has acquired Altair Clinical, Ltd. (Altair Clinical). Altair Clinical is a full service European clinical CRO and provider of global clinical CRO resourcing solutions to pharmaceutical, biotech, and medical device companies. The acquisition expands Accelovance's existing US and Beijing, China offices to include Cambridge, UK, Moscow, Russia, and staff located throughout Europe including Central and Eastern Europe (CEE) and the Middle East and North Africa (MENA). This enhanced geographic coverage supports Accelovance's ability to meet the global needs and capabilities of clinical trial research.

	"We're excited about the global clinical and service expansion opportunities we're able to offer our clients through the acquisition of Altair Clinical. In addition to an expanded geographic footprint, we're adding talented management and staff experience to further enhance our ability to meet the evolving needs of our clients. This acquisition, and our expanded global capabilities and staffing services, provide a proven alternative to existing existing providers of full range CRO services," said Stephen J. Trevisan, CEO of Accelovance.

	Altair Clinical and their staff bring a diverse wealth of knowledge, talent, and experience in offering full service and individual resourcing structures to clients within the pharmaceutical, biotech, and medical device industry. This experience will augment Accelovance's experience in oncology, vaccines, and general medicine.

	"We're delighted to join Accelovance and to bring our expertise and international reach to this great company," said Nigel Trim, Executive Chairman of Altair Clinical. "We believe this acquisition will benefit all clients and significantly enhance Accelovance's ability to provide global services – advancing clinical development of small molecule, biological, and device approvals."